AYTU BIOPHARMA INC (AYTU) Stock Price, Forecast & Analysis
NASDAQ:AYTU • US0547548588
AYTU Key Statistics, Chart & Performance
The current stock price of AYTU is 2.13 USD. In the past month the price decreased by -22.83%. In the past year, price increased by 53.79%.
AYTU Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to AYTU. When comparing the yearly performance of all stocks, AYTU is one of the better performing stocks in the market, outperforming 85.06% of all stocks.
AYTU Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AYTU. AYTU may be in some trouble as it scores bad on both profitability and health.
AYTU Financial Highlights
Over the last trailing twelve months AYTU reported a non-GAAP Earnings per Share(EPS) of -3.55. The EPS decreased by -206.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.46% | ||
| ROE | -56.41% | ||
| Debt/Equity | 1.09 |
AYTU Forecast & Estimates
9 analysts have analysed AYTU and the average price target is 9.52 USD. This implies a price increase of 346.95% is expected in the next year compared to the current price of 2.13.
For the next year, analysts expect an EPS growth of 54.04% and a revenue growth -20.09% for AYTU
AYTU Ownership
AYTU Latest News, Press Relases and Analysis
AYTU Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.99 | 983.195B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 586.544B | ||
| MRK | MERCK & CO. INC. | 22.44 | 301.342B | ||
| PFE | PFIZER INC | 9.18 | 156.812B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 123.651B | ||
| ZTS | ZOETIS INC | 18.44 | 55.813B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.71 | 26.086B | ||
| VTRS | VIATRIS INC | 6.23 | 18.163B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.04 | 12.486B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.27 | 9.135B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AYTU
Company Profile
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. The company is headquartered in Denver, Colorado and currently employs 82 full-time employees. The company went IPO on 2017-10-20. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.
Company Info
AYTU BIOPHARMA INC
7900 E. Union Avenue, Suite 920
Denver COLORADO 80112 US
CEO: Joshua R. Disbrow
Employees: 82
Phone: 17204376580
AYTU BIOPHARMA INC / AYTU FAQ
Can you describe the business of AYTU BIOPHARMA INC?
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. The company is headquartered in Denver, Colorado and currently employs 82 full-time employees. The company went IPO on 2017-10-20. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.
Can you provide the latest stock price for AYTU BIOPHARMA INC?
The current stock price of AYTU is 2.13 USD. The price decreased by -2.29% in the last trading session.
Does AYTU BIOPHARMA INC pay dividends?
AYTU does not pay a dividend.
What is the ChartMill rating of AYTU BIOPHARMA INC stock?
AYTU has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists AYTU stock?
AYTU stock is listed on the Nasdaq exchange.
What is the next earnings date for AYTU stock?
AYTU BIOPHARMA INC (AYTU) will report earnings on 2026-05-12.
What is the Short Interest ratio of AYTU BIOPHARMA INC (AYTU) stock?
The outstanding short interest for AYTU BIOPHARMA INC (AYTU) is 5.63% of its float.